SearchDictionaryMobileLogin

Haemophilus influenzae type b conjugate vaccine diluted tenfold in diphtheria-tetanus-whole cell pertussis vaccine: a randomized trial.

AbstractBACKGROUND: Despite their proven efficacy Haemophilus influenzae type b (Hib) conjugate vaccines are not given to most children in the developing world in the face of an estimated global Hib disease burden of nearly 2 million cases per annum. A major barrier to the introduction of the vaccine would be overcome by diluting the vaccine 10-fold in diphtheria-tetanus-whole cell pertussis (DTP). We report a randomized trial comparing the use of Hib conjugate vaccine diluted in a multidose vial of DTP with that of the full Hib dose. METHODS: We randomized 168 infants to receive either the full dose Hib polysaccharide-tetanus toxoid conjugate (PRP-T) vaccine or a 1/10 dilution prepared by reconstituting the full dose in a 10-dose DTP vial. Infants were vaccinated at 6, 10 and 14 weeks of age and received a full dose as a test of immunologic memory at 9 months of age. Sera were collected at each visit and at 1 week after the booster dose. Serum anti-capsular PRP antibody concentrations were measured by enzyme-linked immunosorbent assay. RESULTS: After the primary vaccination series, 95% of infants in the full dose arm and 94% of infants in the 1/10 dose arm achieved anti-PRP IgG antibody concentrations of > or = 1.0 microg/ml. Infants receiving the diluted vaccine had significantly higher titers of anti-PRP antibody in response to the booster dose (151.36 microg/ml vs. 68.55 microg/ml, P = 0.009). CONCLUSIONS: The 1/10 dose of PRP-T was as immunogenic and safe as the full dose. The technique of diluting a single dose of PRP-T in a 10-dose DTP vial could potentially allow the widespread introduction of Hib vaccine in resource-poor countries currently unable to afford full dose Hib conjugate vaccine.
AuthorsMark Nicol, Robin Huebner, Rosalia Mothupi, Helena Käyhty, Nontombi Mbelle, Esther Khomo (Affiliation: Pneumococcal Diseases Research Unit of the Medical Research Council, South African Institute for Medical Research and University of the Witwatersrand, Johannesburg, South Africa.)
JournalThe Pediatric infectious disease journal (Pediatr Infect Dis J) Vol. 21 Issue 2 Pg. 138-41 (Feb 2002) ISSN: 0891-3668 United States
PMID11840081 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Viral
  • Bacterial Capsules
  • Diphtheria-Tetanus-Pertussis Vaccine
  • Haemophilus Vaccines
  • Haemophilus influenzae type b polysaccharide vaccine
  • Polysaccharides, Bacterial
Topics
  • Antibodies, Viral (analysis)
  • Antibody Formation
  • Bacterial Capsules
  • Developing Countries
  • Diphtheria-Tetanus-Pertussis Vaccine (administration & dosage)
  • Dose-Response Relationship, Drug
  • Female
  • Haemophilus Vaccines (administration & dosage, adverse effects, immunology)
  • Humans
  • Infant
  • Male
  • Polysaccharides, Bacterial (administration & dosage, adverse effects, immunology)